Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients

Biomarkers to monitor the degenerative process in Alzheimer's disease would be of great value. We examined the relation between cerebrospinal fluid (CSF) total tau (T-tau), phospho-tau (P-tau) and Abeta42 and magnetic resonance imaging (MRI) measures of brain atrophy. CSF was taken at baseline and MRI at baseline and at 16 months follow-up. At baseline, statistically significantly lower Abeta42 were found with lower brain volume (r=0.55; P<0.0001) and larger ventricular volume (r=-0.53; P<0.001). In contrast, statistically significantly higher T-tau (r=0.47; P<0.001) and P-tau (r=0.41; P=0.005) were found with more marked ventricular widening during the follow-up period. These results suggest that Abeta42 in CSF reflects the stage of the disease, with lower CSF levels as the disease progresses, while T-tau and P-tau reflect the intensity of the disease process, with higher CSF-levels with a more rapid progression.

[1]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[2]  T. Iwatsubo,et al.  Cerebrospinal fluid levels of amyloid β-peptide1–42, but not tau have positive correlation with brain glucose metabolism in humans , 1999, Neuroscience Letters.

[3]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[4]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[5]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[6]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[7]  K. Blennow,et al.  Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment , 2001, Neuroscience Letters.

[8]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[9]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[10]  J. Kornhuber,et al.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.

[11]  K. Blennow,et al.  Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. , 2000, Journal of Alzheimer's disease : JAD.

[12]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[13]  L. Wahlund,et al.  Inheritance of the ApoE ε4 Allele Increases the Rate of Brain Atrophy in Dementia Patients , 1999, Dementia and Geriatric Cognitive Disorders.

[14]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[15]  H. Arai.  Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals , 1997 .

[16]  Nick C Fox,et al.  Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease , 1999, The Lancet.

[17]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[18]  J. Kornhuber,et al.  Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease , 2000, Neurology.